These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17060795)

  • 1. Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis.
    Trattler WB; Luchs J; Majmudar P
    Int Ophthalmol Clin; 2006; 46(4):87-99. PubMed ID: 17060795
    [No Abstract]   [Full Text] [Related]  

  • 2. Epinastine in the management of ocular allergic disease.
    Friedlaender MH
    Int Ophthalmol Clin; 2006; 46(4):85-6. PubMed ID: 17060794
    [No Abstract]   [Full Text] [Related]  

  • 3. Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects.
    Pradhan S; Abhishek K; Mah F
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1135-40. PubMed ID: 19630694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epinastine ophthalmic solution (Elestat).
    Med Lett Drugs Ther; 2004 Apr; 46(1181):35-6. PubMed ID: 15114254
    [No Abstract]   [Full Text] [Related]  

  • 6. Epinastine 0.05% ophthalmic solution in contact lens-wearing subjects with a history of allergic conjunctivitis.
    Nichols KK; Morris S; Gaddie IB; Evans D
    Eye Contact Lens; 2009 Jan; 35(1):26-31. PubMed ID: 19125045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge.
    Mah FS; Rosenwasser LJ; Townsend WD; Greiner JV; Bensch G
    Curr Med Res Opin; 2007 Jun; 23(6):1445-52. PubMed ID: 17559743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
    Tagawa Y; Namba K; Nakazono Y; Iwata D; Ishida S
    Allergol Int; 2017 Apr; 66(2):338-343. PubMed ID: 27720602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo performance of epinastine hydrochloride-releasing contact lenses.
    Minami T; Ishida W; Kishimoto T; Nakajima I; Hino S; Arai R; Matsunaga T; Fukushima A; Yamagami S
    PLoS One; 2019; 14(1):e0210362. PubMed ID: 30699147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.
    Abelson MB; Gomes P; Crampton HJ; Schiffman RM; Bradford RR; Whitcup SM
    Clin Ther; 2004 Jan; 26(1):35-47. PubMed ID: 14996516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice.
    Villareal AL; Farley W; Pflugfelder SC
    Eye Contact Lens; 2006 Dec; 32(6):272-6. PubMed ID: 17099387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
    Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
    Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of topical cyclosporine a 0.05%, cyclosporine a 2%, epinastine hydrochloride 0.05%, and prednisolone acetate 1% on allergic inflammation in an experimental allergic conjunctivitis model.
    Semsettin B; Sinan E; Nigar V
    Cornea; 2013 Nov; 32(11):1465-9. PubMed ID: 24055903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
    Ousler GW; Workman DA; Torkildsen GL
    Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological and clinical profile of epinastine hydrochloride (Alesion Dry Syrup 1%)].
    Ohmura T; Kawasaki T
    Nihon Yakurigaku Zasshi; 2006 Jan; 127(1):37-46. PubMed ID: 16508222
    [No Abstract]   [Full Text] [Related]  

  • 17. Ophthalmic levocabastine for allergic conjunctivitis.
    Med Lett Drugs Ther; 1994 Apr; 36(920):35-6. PubMed ID: 7908401
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and artificial tears in seasonal allergic conjunctivitis.
    Kamis U; Ozturk BT; Ozkagnici A; Gunduz K
    Acta Ophthalmol Scand; 2006 Feb; 84(1):148-9. PubMed ID: 16445458
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical Olopatadine in the Treatment of Allergic Conjunctivitis: A Systematic Review and Meta-analysis.
    Kam KW; Chen LJ; Wat N; Young AL
    Ocul Immunol Inflamm; 2017 Oct; 25(5):663-677. PubMed ID: 27192186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of allergic conjunctivitis in children: the out-patients' department experience (allergic conjunctivitis in children: management and care).
    Napoli G; Allegri P; Musso C; Morchio AA; Callegarini L; Murialdo U; Tanca D; Marrè V
    Eur Ann Allergy Clin Immunol; 2005 Jan; 37(1):21-4. PubMed ID: 15745373
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.